Zimmer Biomet Holdings (ZBH) EBITDA Margin (2009 - 2026)

Zimmer Biomet Holdings' EBITDA Margin history runs 18 years deep, the most recent figure standing at 17.88% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 257.0% year-over-year to 17.88%; the TTM figure through Mar 2026 stood at 14.02% (down 302.0% YoY), while the FY2025 annual figure was 13.34%, down 340.0% from the prior year.
• EBITDA Margin was 17.88% for Q1 2026 at Zimmer Biomet Holdings, up from 6.89% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 19.23% in Q4 2024 to a low of 1.55% in Q4 2022.
• Historically, EBITDA Margin has averaged 14.62% across 5 years, with a median of 15.32% in 2024.
• The sharpest annual moves came in 2023 and 2025: EBITDA Margin surged 1981 bps in 2023, then tumbled 1234 bps in 2025.
• A 5-year view of EBITDA Margin shows it stood at 1.55% in 2022, then surged by 1277 bps to 18.26% in 2023, then increased by 5 bps to 19.23% in 2024, then tumbled by 64 bps to 6.89% in 2025, then soared by 160 bps to 17.88% in 2026.
• The last three EBITDA Margin figures came in at 17.88% (Q1 2026), 6.89% (Q4 2025), and 17.55% (Q3 2025), per Business Quant data.